Nuevolution

Upcoming triggers from small molecule drug discovery engine Nuevolution ( based on public company info - dates are my own estimates based on public company info) Before end of October 2016 BET inhibitor (selective to BD1) - First in class in inflammation Obtain pre-clinical results from mouse models of very underserved diseases fibrosis (IPF) and Lupus (SLE) Before end of November 2016 ROR gamma inhibitor - Second/third in class in inflammation / possibly first to inhibit resistance to standard of care in prostate cancer. Obtain late pre-clinical results from serious prostate cancer (CRPC) and undisclosed target in inflammation. Obtain non-GLP tox re the back up candidate. ...

Allergan köper Nuevolutions konkurrent Vitae Pharma för 639 musd. http://ir.vitaepharma.com/phoenix.zhtml?c=219654&p=irol-newsArticle&ID=2201774 Vitae har en drug discovery maskin som är en blek kopia av Nuevolutions plattform Chemetics. Vitae och Nuevolution kämpar om tätpositionen mot RORgamma targeten, en oerhört viktig target inom autoimmuna sjukdommar. (se Communityanalys) Vitae är före i fas men hade viss toxicitet i hög dos i sin i våras avbrutna phase 2 studie. Nuevolutions börsvärde är idag endast 426 msek eller 50 musd. Många triggers framöver. ...

Webcast på http://www.wsw.com/webcast/rrshq26/nue.st/

Se även community analys från Aug 30-2016. Nuevolution -Big Data approach till läkemedelsutveckling.

Autoimmune diseases is a body’s hyperactive immune response against the substances and tissues normally present in the body. Autoimmune diseases are more commonly caused by genetic, infectious or environmental factors. The prevalence of autoimmune disease is on rise. According to National Institute of Health, approximately 50 million of Americans suffer from autoimmune diseases. The diseases in estimated to be one of the top 10 cause of death in women under the age 65, and is the second highest cause of chronic illness. There are more than 80 clinically different type of autoimmune diseases identified till date. With rising prevalence of autoimmune diseases the demand of drugs used in the treatment for autoimmune disease is also rising. (Future Market Insight) ...